Literature DB >> 6222901

Aminoglutethimide dose and hormone suppression in advanced breast cancer.

A L Harris, M Dowsett, S L Jeffcoate, I E Smith.   

Abstract

The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid. Aminoglutethimide (AG) 250 mg twice a day was as effective as AG 250 mg 3 times a day or AG 250 mg 4 times a day. Side-effects were less at the lowest dosage and were age-related. On-treatment oestrone levels were higher in non-responders to treatment. Lower doses of AG than are currently used may be as effective therapeutically.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6222901     DOI： 10.1016/0277-5379(83)90112-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  14 in total

1.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

Authors:  M Dowsett; A L Harris; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

3.  Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

Authors:  I L Crighton; M Dowsett; A Lal; A Man; I E Smith
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

4.  Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.

Authors:  P E Lønning; D C Johannessen; T Thorsen
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

5.  A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.

Authors:  M Dowsett; A Mehta; J Mansi; I E Smith
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

6.  Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.

Authors:  B A Ponder; R J Shearer; R D Pocock; J Miller; D Easton; C E Chilvers; M Dowsett; S L Jeffcoate
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

7.  Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.

Authors:  A L Harris; J Carmichael; B M Cantwell; M Dowsett
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

8.  A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

Authors:  M Dowsett; A L Harris; R Stuart-Harris; M Hill; B M Cantwell; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

9.  Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

Authors:  M Dowsett; F MacNeill; A Mehta; C Newton; B Haynes; A Jones; M Jarman; P Lonning; T J Powles; R C Coombes
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.

Authors:  A L Harris; M Dowsett; I E Smith; S Jeffcoate
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.